High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy
Few clinical studies investigated the putative link between the activation of immunogenic cell death (ICD) and the oncological outcome. Recent data, published in a Phase 1b trial, demonstrated that an ICD-associated surge in the plasma concentration of high-mobility group box 1 (HMGB1) indicates favorable prognosis in patients with advanced leiomyosarcomas treated with the combination of doxorubicin, dacarbazine and nivolumab.
Authors
- Lucillia Bezu (ORCID: https://orcid.org/0000-0002-3569-6066)
- Guido Kroemer
Institutions
- Université Paris Cité (FR)
- Institut Gustave Roussy (FR)
- Sorbonne Université (FR)
- La Ligue Contre le Cancer (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- European Society of Anaesthesiology (BE)
- Hôpital Européen (FR)
Publication Details
- Journal
- OncoImmunology
- Published
- 2024-11-21
- DOI
- https://doi.org/10.1080/2162402x.2024.2432059
- Citations
- 3
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- Philippe Foundation
- Seerave Foundation
- Equipex
- European Commission
- Agence Nationale de la Recherche
- Fondation pour la Recherche Médicale
- Ligue Contre le Cancer
- Centre National de la Recherche Scientifique
- Institut Universitaire de France
- Institut National Du Cancer
- Labex Immuno-Oncology